Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SION-719 Added to Trikafta in Cystic Fibrosis
NCT07108153Phase 2Completed
- Sponsor
- Sionna Therapeutics, Inc.
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of SION-719 in cystic fibrosis (CF) (2 arms), sponsored by Sionna Therapeutics, Inc. Primary endpoint: Incidence of treatment emergent adverse events. Started Nov 2025; status: completed.
02
Drugs
SION-719
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07108153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108153.